Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06938685 · ClinicalTrials.gov registry record · NA

Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers

A NA study of Diabetic Foot Ulcer, sponsored by NuScience Medical Biologics.

Recruiting
Registry status
NA
Development phase
132
Enrollment target
5
Study locations

NCT06938685: Recruiting NA study of Diabetic Foot Ulcer, sponsored by NuScience Medical Biologics.

NCT06938685 is a NA study of Diabetic Foot Ulcer that is actively recruiting participants, run by NuScience Medical Biologics. The registered enrollment target is 132 participants, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (48% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06938685, a NA study of Diabetic Foot Ulcer, is actively recruiting participants, sponsored by NuScience Medical Biologics.

RECRUITING
Registry status
NA
Development phase
132 participants
Enrollment target
5
Study locations

Study Summary

This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating diabetic foot ulcers.

Primary Outcome

The primary endpoint will be the percentage of target ulcers that achieve complete wound closure.

Conditions Studied

Interventions

  • OTHER Standard of Care
  • OTHER NeoThelium FT

Study Locations (5)

Louisiana

  • MedCentris of Alexandria - Alexandria
  • MedCentris of Monroe - Monroe

Mississippi

  • MedCentris of Natchez - Natchez
  • MedCentris of Picayune - Picayune

Pennsylvania

  • Pace Foot and Ankle Center - Bryn Mawr

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2025-10-06
Est. Completion 2026-10-01
Phase NA
NuScience Medical Biologics

7 total trials

What NCT06938685 shows while recruiting

NCT06938685 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (48% lower).

The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT06938685 lists 5 locations in 3 states (Louisiana, Mississippi, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT06938685 about?

NCT06938685 is a clinical study titled "Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers". This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating diabetic foot ulcers.

What is the current status of trial NCT06938685?

This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2025-10-06. Estimated completion is 2026-10-01.

What conditions does trial NCT06938685 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer.

What interventions are being tested in trial NCT06938685?

The interventions under investigation include: Standard of Care (OTHER), NeoThelium FT (OTHER).

Who is sponsoring clinical trial NCT06938685?

This trial is sponsored by NuScience Medical Biologics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06938685 being conducted?

This trial has 5 study locations across Louisiana, Mississippi, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06938685's enrollment target sits among peer trials

132 29th of 67 higher than 39 of 67 other Diabetic Foot Ulcer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01766297 · 132 participants · Phase 2

    Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

  • NCT04002947 · 132 participants · Phase 2

    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  • NCT04128189 · 132 participants · Phase 3

    Shingrix in Renal Transplant Recipients

  • NCT04199780 · 132 participants · NA

    Effects of tDCS Combined With CBI on Postsurgical Pain

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06938685, the US trial registry maintained by the National Library of Medicine. NCT06938685 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.